IP Library Granted Patent US 11,447,809
Granted Patent B2
US 11,447,809 · App. 16/628,456 · Granted Sep 20, 2022

Evolution of tRNA synthetases

Inventors: David R. Liu (Lexington, MA); David Irby Bryson, Jr. (Dorchester, MA)
Assignee: President and Fellows of Harvard College
C12P21/02C12N9/93C12Y601/01026
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,447,809
App. No.
16/628,456
Filed
Jan 3, 2020
Granted
Sep 20, 2022
Kind
B2
Art Unit
1652
USPC
435/69.1
Abstract

The disclosure provides amino acid sequence variants of orthogonal aminoacyl-tRNA synthetases (AARSs) having increased activity and selectivity compared to previous AARSs, and methods of producing the same.

Claims (10)

1. A tRNA synthetase protein variant comprising an amino acid sequence that is at least 85% identical to SEQ ID NO: 20 or SEQ ID NO: 21, and includes at least one mutation at a position selected from V31, T56, H62, and A100.

2. The tRNA synthetase protein variant of claim 1 , wherein the at least one mutation is V31I, T56P, H62Y, A100E, or A100S.

3. The tRNA synthetase protein variant of claim 1 comprising mutations at V31, T56, H62, and A100.

4. The tRNA synthetase protein variant of claim 3 , wherein the mutations are V31I, T56P, H62Y, and A100E.

5. The tRNA synthetase protein variant of claim 1 , wherein the nucleic acid sequence encoding the amino acid sequence comprises one or more premature stop codons.

6. A chimeric pyrrolysyl-tRNA synthetase (PylRS) protein variant comprising:

(i) a first portion comprising amino acid residues 1-149 of Methanosarcina barkeri PylRS (SEQ ID NO: 20); and

(ii) a second portion comprising amino acid residues 185-454 of Methanosarcina mazei PylRS (SEQ ID NO: 21), wherein the first portion or the second portion comprises at least one of the amino acid substitutions set forth in Tables 2-6.

7. The chimeric PylRS protein variant of claim 6 , wherein the chimeric PylRS protein variant comprises an amino acid substitution at at least one of the following positions: V31, T56, H62, or A100.

8. The chimeric PylRS protein variant of claim 7 , wherein the amino acid substitution is V31I, T56P, H62Y, A100E, or any combination thereof.

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 8, 2023
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064852/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2022
From: BRYSON, DAVID IRBY, JR.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 059635/0127 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2022
From: LIU, DAVID R.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 059635/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2022
From: HOWARD HUGHES MEDICAL INSTITUTE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 059635/0302 →
Continuity (3)
Provisional Application 62535090 · Jul 20, 2017
Provisional Application 62529320 · Jul 6, 2017
Related Publication 20220154237A1 · May 19, 2022
Cited By (2)
US 12,398,390 US 12,655,182